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Abstract
In previous studies, we demonstrated that esters of bendamustine containing a
basic moiety are far more cytotoxic anticancer agents than their parent compound
and that the substitution of the labile ester moiety by a branched ester or an amide
markedly increases stability in the blood plasma. In the current study, we showed
that this substitution was bioisosteric. Aiming at increased cytotoxicity, we in-
troduced the same modification to related nitrogen mustards: 6‐isobendamustine,
chlorambucil, and melphalan. The synthesis was accomplished using the
coupling reagents N,N′‐dicyclohexylcarbodiimide or 2‐(1H‐benzotriazole‐1‐yl)‐1,1,3,3‐
tetramethylaminium tetrafluoroborate. Cytotoxicity against a panel of diverse cancer
cells (carcinoma, sarcoma, and malignant melanoma) was assessed in a kinetic che-
mosensitivity assay. The target compounds showed cytotoxic or cytocidal effects at
concentrations above 1 µM: a striking enhancement over bendamustine and
6‐isobendamustine, both ineffective against the selected cancer cells at concentrations
up to 50 µM, and a considerable improvement over chlorambucil, showing some po-
tency only against the sarcoma cells. Melphalan was almost as effective as the target
compounds—derivatization only provided a small improvement. The novel cytostatics
are of interest as model compounds for analyzing a correlation between cytotoxicity
and membrane transport and for the treatment of malignancies.
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1 | INTRODUCTION
Cancer is the second leading cause of death worldwide.[1] Surgery
and radiation are local therapies and cannot eradicate metastatic
cancer, where every organ in the body needs to be reached.[2] By
contrast, chemotherapy works systemically and is the most effective
treatment for disseminated tumors.[2,3] The era of chemotherapy
began in 1942 with the discovery of nitrogen mustards—originally
produced as chemical warfare agents—as a remedy for cancer.[2,4] A
basic chemical reaction underlies the mechanism of action of
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nitrogen mustards, namely the intramolecular cyclization in a polar
solvent to form an aziridnium cation, which reacts readily with bio-
nucleophiles (Figure 1), for example nitrogen in the DNA. This re-
action leads to the formation of DNA interstrand crosslinks, which
prevents cell replication and ultimately causes cell death.[4,5]
Inspired by this success, further, improved DNA‐alkylating
agents of the nitrogen mustard type were developed as che-
motherapeutics, such as chlorambucil, melphalan, or bendamustine.
Chlorambucil (2) (Figure 2) was first synthesized by Everett
et al.[6] in 1953. The nitrogen mustard moiety (i.e., the bis(2‐
chloroethyl)amino moiety, also called N‐lost moiety) was attached to
a phenyl ring, which withdraws electrons from the nitrogen atom,
thereby disfavoring aziridinium ion formation, which renders the
nitrogen mustard moiety less reactive toward the nucleophilic at-
tack.[7] Therefore, chlorambucil and other aromatic analogs are suf-
ficiently deactivated so that they can reach their target DNA sites
before being degraded by reacting with collateral nucleophiles, re-
sulting in reduced toxic side effects and allowing oral administra-
tion.[7] The butanoic acid side chain makes the compound
hydrophilic.[8] Chlorambucil is sold, among others, under the brand
name of Leukeran and is indicated in the treatment of chronic lym-
phocytic leukemia (CLL), Hodgkin and non‐Hodgkin lymphomas (HL
and NHL), as well as breast and ovarian carcinomas.[5,9,10]
Melphalan (3) (Figure 2) differs from chlorambucil in the length of
the alkanoic acid side chain and in the amino group attached to the
latter—the amino acid L‐phenylalanine is the “carrier” of the N‐lost
moiety. Melphalan was first synthesized in 1954 by Bergel et al.,[11]
aiming at increased tumor selectivity. Indeed, melphalan is imported by
amino acid transporters[12] whose expression is upregulated in cancer
cells.[13] Melphalan is used for treating various malignancies including
multiple myeloma (MM), ovarian cancer, breast cancer, and melanoma,
and is sold, among others, under the trade name of Alkeran.[14,15]
Bendamustine (4) (Figure 3) was initially synthesized in 1963 by
Ozegowski et al.[16,17] in the former German Democratic Republic
and was introduced into the market there.[18,19] It distinguishes itself
from chlorambucil in the central benzimidazole ring, which is unique
to bendamustine and was intended to include antimetabolite prop-
erties, which, however, have not yet been confirmed.[17,18] Never-
theless, bendamustine displays a unique mechanism of action, as it
inhibits mitotic checkpoints, causes inefficient DNA repair, and in-
duces the expression of the protein p53, a tumor suppressor, which
initiates apoptosis.[20,21] Bendamustine was approved in the Federal
Republic of Germany after the iron curtain had fallen, and today it is
sold, among others, under the brand name of Ribomustin for CLL,
indolent NHL, and MM.[19,22] In the United States of America, the
drug is marketed, among others, under the brand name of Treanda
and is approved for CLL and indolent NHL.[18,19] The assets of
bendamustine are a favorable side‐effect profile,[18] the lack of cross‐
resistances, with many other alkylating agents,[19] and its superiority
to chlorambucil in previously untreated patients with CLL.[22]
Bendamustine is usually dosed intravenously; however, there have
been a couple of patent applications aiming at formulations for oral ad-
ministration.[23,24] Esterification of the carboxylic acid moiety may in-
crease the chances of oral application and, furthermore, has been
reported to enhance the hydrolytic stability of the N‐lost moiety (for
different reasons).[25–27] The increasing interest in esters of bendamus-
tine prompted our working group to perform a study on the pharma-
cological properties of the latter. It was revealed that esters of
bendamustine are by far more potent cytotoxic agents than the parent
compound, especially esters comprising basic moieties, which are charged
under physiological conditions, for example, the 2‐pyrrolidinoethyl ester
5[28] (Figure 3). The basic esters show a pronounced cellular accumula-
tion for reasons not yet identified, but transport proteins may be in-
volved.[28] However, the basic esters turned out to be especially prone to
hydrolysis at the ester bond in the blood plasma, which was attributed to
their similarity to substrates of unspecific cholinesterases.[29] We were
able to overcome this obstacle by substituting the linear ester moiety in 5
by a branched ester (compound 6), which increased the stability to an
acceptable level,[29] and so did the replacement of the ester by an amide
bond (compound 7; unpublished data). Bendamustine, its derivatives 5–7,
and their respective half‐lives in the human blood plasma are depicted in
Figure 3. The decomposition of bendamustine is due to the hydrolysis of
the carbon–chlorine bonds of the N‐lost moiety.
The preparation of 7 and the cytotoxicity analysis of 6 and 7
have not yet been reported, which are a part of the present study.
As other anticancer agents are structurally very similar to bend-
amustine, it is conceivable that these can be improved by the same
F IGURE 1 The mechanism of the reaction of nitrogen mustards with nucleophiles (Nu−), here shown for mechlorethamine (1)
F IGURE 2 Structures of the nitrogen mustard anticancer agents
chlorambucil (2) and melphalan (3)
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modification. Aiming at increased cytotoxicity, the present study com-
prises the synthesis and cytotoxicity analysis of basic derivatives of fur-
ther members of the nitrogen mustard family, especially chlorambucil
and melphalan. In addition, we considered an isomer of bendamustine
(6‐isobendamustine), which we recently described in a patent
application.[30,31] Cytotoxicity analyses of 6‐isobendamustine are still
pending, and this compound serves as another example of increasing the
cytotoxicity of nitrogen mustards by derivatization. A pyrrolidinoalkyl
chain was introduced into the structure of 6‐isobendamustine,
chlorambucil, and melphalan via amide or branched ester formation
(Figure 3), as these moieties previously proved superior to a linear ester
group in terms of stability in the blood plasma.[29]
2 | RESULTS AND DISCUSSION
2.1 | Synthesis
The anticancer agents bendamustine, chlorambucil, and melphalan
are marketed drugs. 6‐Isobendamustine (9)[30,31] (here,
isobendamustine), which, in contrast to conventional bendamustine,
bears the N‐lost moiety in position‐6 (instead of position‐5) of the
benzimidazole ring, is not commercially available. The latter was
prepared from 4‐(1‐methyl‐6‐bis(2‐hydroxyethyl)aminobenzimid
azol‐2‐yl)butyric acid ethyl ester (8), which we received as a kind
gift from Gemini PharmChem. Compound 8 was first treated with
the chlorinating agent thionyl chloride and then with hydrochloric
acid to hydrolyze the ester bond (Scheme 1).
The esters and amides were prepared from their respective
parent compounds and a pyrrolidinoalkyl alcohol or amine. The
bendamustine ester 6 was synthesized with the help of the coupling
reagent N,N′‐dicyclohexylcarbodiimide (DCC), as we described
previously[29]; for the preparation of the novel bendamustine amide
7, the coupling reagents 2‐(1H‐benzotriazole‐1‐yl)‐1,1,3,3
‐tetramethylaminium tetrafluoroborate (TBTU) and N,N‐
diisopropylethylamine (DIPEA) were used (Scheme 2). Iso-
bendamustine was converted to the ester 10 and the amide 11 in
the same way as compounds 6 and 7, respectively (Scheme 2). The
chlorambucil ester 12 could not be synthesized with DCC, but
coupling with TBTU and DIPEA was successful, and the same
F IGURE 3 Structures of the nitrogen mustard anticancer agent bendamustine (4) and its derivatives 5, 6, and 7, as well as their respective
half‐lives in human blood plasma, and the rationale of the present study
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SCHEME 1 The synthesis of 6‐
isobendamustine (9). Reagents and conditions:
(I) SOCl2, dichloromethane, reflux, 60min; (II)
6M HCl aq., 90°C, 2 h
SCHEME 2 The synthesis of the target compounds 6, 7, 10–13, 15, and 16. Reagents and conditions: (a) 1‐(pyrrolidin‐1‐yl)propan‐2‐ol,
N,N′‐dicyclohexylcarbodiimide, dimethylformamide (DMF), 0°C, 15min→ 80°C (microwave), 30 min; (b) respective alcohol or amine,
2‐(1H‐benzotriazole‐1‐yl)‐1,1,3,3‐tetramethylaminium tetrafluoroborate, N,N‐diisopropylethylamine, DMF, rt, overnight or 60–80°C
(microwave), 45–120min; (c) Boc2O, NaHCO3, tetrahydrofuran/H2O 1:1, rt, 30 min; (d) trifluoroacetic acid, dichloromethane, rt, 2 h
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reagents were used to prepare the chlorambucil amide 13 (which is
already known in the literature[32]) (Scheme 2). Melphalan was first
tert‐butyloxycarbonyl (boc)‐protected (to compound 14), then
treated with the respective alcohol or amide and the established
coupling reagents TBTU and DIPEA, and subsequently deprotected
to the melphalan ester 15 or the amide 16 (Scheme 2).
2.2 | Cytotoxicity
The cytotoxicity of the target compounds was investigated in a
kinetic chemosensitivity assay, which allows the distinction between
cytotoxic, cytostatic, and cytocidal drug effects.[33] The effects
against the following three cancer cell lines were determined: a
carcinoma (colorectal adenocarcinoma, HT‐29), a sarcoma
(osteosarcoma, MG‐63), and a malignant melanoma (SK‐MEL‐3).
2.2.1 | Bendamustine and derivatives
In accordance with our previous report,[28] bendamustine proved
ineffective against HT‐29 carcinoma cells (Figure 4). Also, the che-
mosensitivity of MG‐63 osteosarcoma and SK‐MEL‐3 melanoma cells
was very low with slight cytotoxic effects at concentrations above
30 µM. In contrast, the branched ester 6 and the amide 7 exhibited a
distinct increase in cytotoxicity as compared with the parent
(a) (b) (c)
F IGURE 4 Cytotoxicity of bendamustine (4), its ester 6, and its amide 7 against HT‐29 cells (a), MG‐63 cells (b), and SK‐MEL‐3 cells (c).
Cytotoxic/cytocidal effects correspond to the left y‐axes. The growth curves of untreated control cells (open circles) correspond to the right
y‐axes. Data are mean values ± SEM of two to four independent experiments, each performed in octuplicate
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compound, showing cytocidal effects against the treated cancer cells
at concentrations of 10–30 µM. This is in good accordance with our
previously examined linear esters of bendamustine.[28] Thus, the
replacement of the linear ester moiety by a branched ester or an
amide group did not only increase the stability in human blood
plasma but also proved to be bioisosteric.
2.2.2 | Isobendamustine and derivatives
The comportment of isobendamustine in the chemosensitivity assay
was almost identical to its isomer bendamustine—all three cell lines
were refractory against treatment with isobendamustine (Figure 5).
In contrast, the basic derivatives 10 and 11 exerted a pronounced
effect against the three cell lines (cytocidal at concentrations be-
tween 10 and 30 µM), which is in analogy with the basic derivatives
of bendamustine. Hence, the method of increasing the cytotoxicity
by the introduction of a basic moiety was successfully applied to the
6‐isomer of bendamustine, and it became obvious that the change in
the position of the nitrogen mustard moiety at the benzimidazole
ring is well tolerated.
2.2.3 | Chlorambucil and derivatives
Chlorambucil displays a pronounced structural difference from
bendamustine, as it bears a phenyl ring instead of a benzimidazole
moiety. Its effect against HT‐29 carcinoma cells and SK‐MEL‐3
melanoma cells was rather weak, whereas it showed a cytocidal ef-
fect against MG‐63 osteosarcoma cells at a concentration of 30 µM
(Figure 6). The conversion into the basic ester 12 or amide 13
markedly increased the cytotoxicity as compared with the parent
(a) (b) (c)
F IGURE 5 Cytotoxicity of isobendamustine (9), its ester 10, and its amide 11 against HT‐29 cells (a), MG‐63 cells (b), and SK‐MEL‐3 cells (c).
Cytotoxic/cytocidal effects correspond to the left y‐axes. The growth curves of untreated control cells (open circles) correspond to the right
y‐axes. Data are mean values ± SEM of two to four independent experiments, each performed in octuplicate
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compound, both derivatives showing cytocidal effects against HT‐29
and MG‐63 cells at concentrations of 1–10 µM and against SK‐MEL‐
3 cells, which were refractory against treatment with chlor-
ambucil, at concentrations of 10–30 µM. The chlorambucil amide was
more potent than the ester; for instance, the amide exhibited a cy-
tocidal effect against MG‐63 osteosarcoma cells at a concentration
as low as 1 µM, whereas a concentration of 10 µM of the ester was
necessary to achieve the same effect. Taken together, the in-
troduction of a basic moiety via an ester or amide bond turned out an
effective means to increase the potency of chlorambucil.
2.2.4 | Melphalan and derivatives
Melphalan, an L‐phenylalanine‐nitrogen mustard, was more effective
against the three cell lines than bendamustine, isobendamustine, or
chlorambucil, which may be due to its property as an amino acid
transporter substrate, causing increased cellular uptake. Melphalan
showed a cytocidal effect on carcinoma HT‐29 and osteosarcoma
MG‐63 cells at concentrations of 30 and 10 µM, respectively
(Figure 7). The chemosensitivity of SK‐MEL‐3 cells was lower, with a
cytostatic effect at a concentration of 30 µM. The basic ester 15 and
amide 16 showed effects similar to the parent compound against
MG‐63 cells. However, HT‐29 and SK‐MEL‐3 cells exhibited a higher
response upon treatment with 15 and 16 than when treated with
melphalan (cytocidal effects at concentrations of 3–30 µM). As in the
case of the chlorambucil derivatives, the amide was somewhat more
potent than the ester. All in all, only a slight improvement in cytotoxicity
of melphalan could be achieved by the introduction of a basic moiety.
Comparing the basic derivatives of bendamustine, isobendamus-
tine, chlorambucil, and melphalan, it becomes apparent that they all
display similar potencies—the growth curves of the individual cell lines
(a) (b) (c)
F IGURE 6 Cytotoxicity of chlorambucil (2), its ester 12, and its amide 13 against HT‐29 cells (a), MG‐63 cells (b), and SK‐MEL‐3 cells (c).
Cytotoxic/cytocidal effects correspond to the left y‐axes. The growth curves of untreated control cells (open circles) correspond to the right
y‐axes. Data are mean values ± SEM of two to four independent experiments, each performed in octuplicate
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upon treatment with 6, 7, 10–13, 15, and 16 are very much alike. This
can be taken as a hint that the enhancement of cytotoxicity is due to
the same mechanism, for instance, increased cellular uptake. As the
basic pyrrolidine ring is protonated under physiological conditions, the
involvement of cation transporters is conceivable. This would also ex-
plain the smaller potency difference between melphalan and its
derivatives—contrary to bendamustine and chlorambucil, melphalan is
imported into the cell by amino acid transporters,[12] which is why the
cellular uptake does not leave much room for optimization.
3 | CONCLUSION
Previously, we have shown that esters of bendamustine are by far
more cytotoxic anticancer agents than their parent compound,
especially those containing a basic moiety. As the latter was rapidly
cleaved in the human blood plasma, the labile ester moiety was
substituted by a branched ester, resulting in compound UR‐Ant26
(6) or an amide group, yielding UR‐Ant16 (7), both of which markedly
increased the stability. In the current study, the cytotoxicity of
compounds 6 and 7 was examined. By analogy with the previous
linear esters, they showed cytocidal effects at concentrations be-
tween 10 µM and 30 µM—a striking increase in cytotoxicity as
compared with bendamustine, which was practically ineffective
against the treated cells. These results verify that the replacement of
the labile ester moiety by a branched ester or an amide was
bioisosteric.
In the hope that this approach of increasing the cytotoxicity
would be applicable to other, related nitrogen mustard anticancer
agents, basic esters and amides of 6‐isobendamustine (compounds
UR‐Ant45 [10] and UR‐Ant48 [11]), chlorambucil (compounds
UR‐Ant66 [12] and UR‐Ant55 [13]), and melphalan
(a) (b) (c)
F IGURE 7 Cytotoxicity of melphalan (3), its ester 15, and its amide 16 against HT‐29 cells (a), MG‐63 cells (b), and SK‐MEL‐3 cells (c).
Cytotoxic/cytocidal effects correspond to the left y‐axes. The growth curves of untreated control cells (open circles) correspond to the right
y‐axes. Data are mean values ± SEM of two to four independent experiments, each performed in octuplicate
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(compounds UR‐Ant65 [15] and UR‐Ant39 [16]) were synthesized. The
reaction of the respective parent compound with a pyrrolidinoalkyl al-
cohol or amide and the coupling reagent DCC or TBTU yielded the target
compounds. Cytotoxicity against carcinoma, sarcoma, and melanoma
cells was assessed in a kinetic chemosensitivity assay. The novel deri-
vatives showed cytotoxic or cytocidal effects at concentrations above
1 μM. This constitutes a striking enhancement over 6‐isobendamustine,
which was ineffective against the selected cancer cells. These results are
very similar to bendamustine and its derivatives, which shows that the
constitution isomerism, that is, the change in the position of the N‐lost
moiety, is well tolerated. Also, an ample improvement over chlorambucil
was achieved, which only showed a weak potency against the sarcoma
cells. Melphalan was almost as effective as the target compounds—
derivatization provided only a small increase in cytotoxicity. It can be
speculated that the introduction of a basic moiety confers substrate
properties of (cation) transporters, thereby increasing cellular uptake and
ultimately cytotoxicity. This would explain the comparable meager en-
hancement achieved by derivatization of melphalan—the latter already
exploits membrane transport systems, as it is a substrate of amino acid
transporters.[12]
Taken together, the novel nitrogen mustard chemotherapeutics can
be considered interesting molecular tools for the analysis of a correlation
between cytotoxicity and membrane transport mechanisms. Further-
more, the increased antiproliferative activity suggests higher efficacy in
the treatment of malignancies for which the parent compound is
approved and a possible extension of the scope of indications.
4 | EXPERIMENTAL
4.1 | Chemistry
4.1.1 | General experimental conditions
Chemicals and solvents were purchased from commercial suppliers
(Sigma Aldrich, Merck, VWR, Thermo Fisher Scientific, and TCI) and
used without further purification unless stated otherwise. Bend-
amustine was a kind gift from Arevipharma. 4‐(1‐Methyl‐6‐bis(2‐
hydroxyethyl)aminobenzimidazol‐2‐yl)butyric acid ethyl ester was a
kind gift from Gemini PharmChem. Reactions requiring anhydrous
conditions were carried out in dried reaction vessels under an at-
mosphere of argon and anhydrous solvents were used. Millipore
water was used throughout for the preparation of buffers and high‐
performance liquid chromatography (HPLC) eluents. Acetonitrile
(MeCN) for HPLC (gradient grade) was obtained from Merck.
Microwave reactions were carried out in an Initiator 8
microwave reactor (Biotage).
Thin‐layer chromatography (TLC) was performed on TLC Silica gel
60 F254 aluminum plates (Merck). Visualization was accomplished by
UV irradiation at wavelengths of 254 and 366 nm or by staining with
ninhydrin (1.5 g ninhydrin, 5 ml acetic acid, and 500 ml 95% ethanol).
The nuclear magnetic resonance (NMR) spectra (see the
Supporting Information) were recorded on an Avance 400
instrument (9.40 T, 1H: 400MHz, 13C: 101MHz) or an Avance 600
instrument with a cryogenic probe (14.1 T, 1H: 600MHz, 13C:
151MHz) (Bruker) with TMS as an external standard. The high‐
resolution mass spectrometry (HRMS) analysis (see the Supporting
Information) was performed on an Agilent 6540 UHD Accurate‐Mass
Q‐TOF LC/MS system (Agilent Technologies) using an ESI source.
Preparative HPLC was performed on a system from Knauer, con-
sisting of two K‐1800 pumps and a K‐2001 detector. A Nucleodur 100‐5
C18 (5 µm, 110Å, 250×21mm; Macherey‐Nagel) (compound 7) or a
Kinetex® XB‐C18 (5 µm, 100Å, 250×21.2mm; Phenomenex) (all other
compounds) served as RP columns at flow rates of 16ml/min and 15ml/
min, respectively. Mixtures of MeCN and 0.1% aq trifluoroacetic acid
(TFA) were used as the mobile phase. The detection wavelength was set
to 220 nm throughout. The solvent mixtures were removed by lyophili-
zation using an Alpha 2‐4 LD lyophilization apparatus (Christ) equipped
with an RZ 6 rotary vane vacuum pump (Vacuubrand).
Analytical HPLC of all compounds, except 12 and 15, was per-
formed on a system from Thermo Separation Products (Dreieich),
composed of an SN400 controller, a P4000 pump, a Degassex
DG‐4400 degasser (Phenomenex), an AS3000 autosampler, and a
Spectra Focus UV–visble detector. A Nucleodur 100‐5 C18 (5 μm,
250 × 4.0mm; Macherey‐Nagel) (compound 7) or a Kinetex®
XB‐C18 (5 µm, 100Å, 250 × 4.6mm; Phenomenex) (all other com-
pounds) served as RP columns at a flow rate of 0.75ml/min. The oven
temperature was set to 30°C throughout. Mixtures of MeCN (A) and
0.05% aq TFA (B) were used as the mobile phase and degassed with
helium. The detection wavelength was set to 220 nm throughout. So-
lutions for injection (100 µM) were prepared in a mixture of A and B,
corresponding to the mixture at the start of the gradient. The following
linear gradient was applied: 0–30min: A/B 20:80–95:5, 30–35min: A/B
95:5. Analytical HPLC of compounds 12 and 15 was performed on a
system from Agilent Technologies (Santa Clara) (Series 1100), com-
prising a G1312A binary pump equipped with a G1379A degasser, a
G1329A ALS autosampler, a G1316A COLCOM thermostated column
compartment, and a G1314A VWD detector. A Kinetex® C18 (2.6 µm,
100Å, 100 × 3mm; Phenomenex) served as an RP column at a flow rate
of 0.4ml/min. The oven temperature was set to 30°C throughout.
Mixtures of MeCN (A) and 0.05% aq TFA (B) were used as the mobile
phase. The detection wavelength was set to 220 nm throughout. Solu-
tions for injection (100 µM) were prepared in a mixture of A and B,
corresponding to the mixture at the start of the gradient. The following
linear gradient was applied: 0–12min: A/B 20:80–95:5, 12–15min: A/B
95:5. Retention (capacity) factors were calculated from retention times
(tR) according to k = (tR − t0)/t0 (t0 = dead time of the respective HPLC
system).
The InChI codes of the investigated compounds, together with some
biological activity data, are provided as Supporting Information.
4.1.2 | General procedure 1 for ester bond formation
The respective carboxylic acid (1.0 eq) was dissolved in anhydrous
DMF (0.2–0.3M) in a microwave reaction vessel. 1‐(Pyrrolidin‐1‐yl)
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propan‐2‐ol (1.5 eq) was added and the stirred mixture was cooled
down to 0°C using an ice bath. DCC (1.1 eq) was added and stirring
was continued at 0°C for 15min and at 80°C in a microwave reactor
for 30min. The mixture was subjected to preparative HPLC (eluent:
MeCN/0.1% aq TFA) and the eluate was lyophilized.
4.1.3 | General procedure 2 for ester bond formation
Under dry conditions, the respective carboxylic acid (1.0 eq) was
dissolved in anhydrous DMF (0.2–0.3M) in a microwave reaction
vessel. DIPEA (2.0 eq) and the coupling reagent TBTU (1.0 eq) were
added, and the solution was stirred at room temperature for 5min.
1‐(Pyrrolidin‐1‐yl)propan‐2‐ol (1.5 eq) was added and stirring was
continued for another 45min at 80°C in a microwave reactor. The
mixture was subjected to preparative HPLC (eluent: MeCN/0.1% aq
TFA) and the eluate was lyophilized. In the case of boc‐protected
compounds, work‐up and deprotection preceded purification of the
final product by preparative HPLC.
4.1.4 | General procedure for amide bond formation
Under dry conditions, the respective carboxylic acid (1.0 eq) was dis-
solved in anhydrous DMF (0.2–0.3M) in a microwave reaction vessel or a
round‐bottom flask. DIPEA (2.0–3.0 eq) and the coupling reagent TBTU
(1.0 eq) were added and the solution was stirred at room temperature
for 5min. The appropriate amine (1.0–1.1 eq) was added and stirring was
continued for another 45–120min at 60–80°C in a microwave reactor or
at room temperature overnight. The mixture was subjected to pre-
parative HPLC (eluent: MeCN/0.1% aq TFA) and the eluate was lyophi-
lized. In the case of boc‐protected compounds, work‐up and deprotection




Compound 7 was prepared according to the general procedure for
the amide bond formation (in a round‐bottom flask with stirring over-
night). The reaction was carried out using bendamustine (100mg,
0.279mmol, 1.0 eq), TBTU (98.6mg, 0.307mmol, 1.1 eq), DIPEA (52.2 µl,
0.307mmol, 1.1 eq), 2‐(pyrrolidin‐1‐yl)ethan‐1‐amine (35.4 µl,
0.279mmol, 1.0 eq), and DMF (1ml). Preparative HPLC (0–30min:
MeCN/0.1% aq TFA 19:81–55:45, tR = 13.0min) yielded 7 as a yellowish
resin (97.5mg, 0.143mmol, 51%). 1H NMR (600MHz, CDCl3): δ
(ppm) =11.43 (s, 1H), 8.24 (t, J=4.9Hz, 1H), 7.39 (d, J=9.2Hz, 1H), 6.98
(d, J=2.3Hz, 1H), 6.95 (dd, J=9.2Hz, J=2.3Hz, 1H), 3.89 (s, 3H), 3.81 (t,
J=6.6Hz, 6H), 3.67 (t, J=6.6Hz, 4H), 3.49 (q, J=5.4Hz, 2H), 3.24 (t,
J=5.4Hz, 2H), 3.19 (t, J=7.4Hz, 2H), 2.89 (br s, 2H), 2.39 (t, J=6.7Hz,
2H), 2.18 (qi, J=7.1Hz, 2H), and 2.08 (br s, 4H). 13C NMR (150MHz,
CDCl3): δ (ppm) = 173.0, 162.1 (TFA), 161.9 (TFA), 161.6 (TFA), 161.4
(TFA), 151.5, 146.1, 132.8, 125.1, 117.5 (TFA), 115.5 (TFA), 112.9, 112.3,
96.4, 55.0, 54.4 (2C), 54.1 (2C), 40.6 (2C), 35.7, 34.3, 31.0, 24.7, 23.2 (2C),
and 22.5. Reversed‐phase high‐performance liquid chromatography (RP‐
HPLC) (220 nm): 99% (tR =7.8min, k=2.3). HRMS (ESI): m/z
[M+H]+ calcd. for C22H34Cl2N5O
+: 454.2135, found: 454.2135.
C22H33Cl2N5O·C4H2F6O4 (454.44+ 228.05).
4‐{6‐[Bis(2‐chloroethyl)amino]‐1‐methyl‐1H‐benzo[d]imidazol‐2‐yl}‐
butanoic acid (6‐isobendamustine) hydrotrifluoroacetate (9) [30,31]
4‐(1‐Methyl‐6‐bis(2‐hydroxyethyl)aminobenzimidazol‐2‐yl)‐
butyric acid ethyl ester (800mg, 2.29mmol, 1.0 eq) was dissolved in
dichloromethane (DCM) and the chlorinating agent thionyl chloride
(498 µl, 6.87mmol, 3.0 eq) was added dropwise. The mixture was
refluxed for 60min and the volatiles were removed under reduced
pressure. The ester bond was hydrolyzed with 6 M HCl aq (4ml)
90°C for 2 h. The mixture was washed with DCM to remove lipo-
philic impurities and isobendamustine hydrochloride was pre-
cipitated by adding 10 M NaOH aq until a pH of 0–1 was reached.
Recrystallization in isopropanol yielded isobendamustine free base
as a brownish solid (346mg, 0.966mmol, 42%). For further pur-
ification, 50mg of the substance was subjected to preparative HPLC
(gradient: 0–30min: MeCN/0.1% aq TFA 25:75–55:45, tR = 13.0min)
and the eluate was lyophilized, yielding compound 9 as a brownish
resin (61.8 mg, 0.131mmol, 94%). Analytical and pharmacological
characterization was performed with the HPLC‐purified substance.
1H NMR (600MHz, deuterated dimethyl sulfoxide [DMSO‐d6]): δ
(ppm) = 14.70 (br s, 1H), 12.26 (br s, 1H), 7.58 (d, J = 9.03 Hz, 1H),
7.11 (d, J = 2.28 Hz, 1H), 7.08 (dd, J = 9.03 Hz, J = 2.28 Hz, 1H), 3.90
(s, 3H), 3.86 (t, J = 6.57 Hz, 2H), 3.80 Hz (t, J = 6.66 Hz, 4H), 3.15 (t,
J = 7.74 Hz, 2H), 2.41 (t, J = 7.1 Hz, 2H), and 2.00 (qi, J = 7.56 Hz, 2H).
13C NMR (151MHz, DMSO‐d6): δ (ppm) = 173.7, 158.5 (TFA), 158.3
(TFA), 158.1 (TFA), 157.8 (TFA), 151.8, 145.4, 134.3, 121.9, 117.5
(TFA), 115.6 (TFA), 114.5, 112.7, 94.0, 52.4 (2C), 41.2 (2C), 32.5,
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30.8, 24.2, and 21.4. RP‐HPLC (220 nm): 98% (tR = 11.7min, k = 2.9).
HRMS (ESI): m/z [M+H]+ calcd. for C16H22Cl2N3O2
+: 358.1084,
found: 358.1104. C16H21Cl2N3O2·C2HF3O2 (358.26 + 114.02).
1‐(Pyrrolidin‐1‐yl)propan‐2‐yl 4‐{6‐[bis(2‐chloroethyl)amino]‐1‐
methyl‐1H‐benzo[d]imidazol‐2‐yl}butanoate (isobendamustine 1‐
methyl‐2‐pyrrolidinoethyl ester) bis(hydrotrifluoroacetate) (10)
Compound 10 was prepared according to the general procedure 1
for the ester bond formation. The reaction was carried out using iso-
bendamustine (75mg, 0.209mmol, 1.0 eq), 1‐(pyrrolidin‐1‐yl)propan‐2‐ol
(40.6mg, 0.314mmol, 1.5 eq), DCC (47.5mg, 0.230mmol, 1.1 eq), and
DMF (0.5ml). A yellow coloration and a white precipitate could be ob-
served. Preparative HPLC (0–30min: MeCN/0.1% aq TFA 20:80–55:45,
tR = 14.5min) yielded 10 as a brownish resin (32.8mg, 0.047mmol, 22%).
More than one diastereoisomer was evident in the NMR spectra. 1H
NMR (600MHz, DMSO‐d6): δ (ppm) = 15.03 (br s, 1H), 10.18 (s, 1H), 7.59
(d, J=9.13Hz, 1H), 7.12 (d, J=2.23Hz, 1H), 7.08 (dd, J=9.13Hz,
J=2.23Hz, 1H), 5.13 (m, 1H), 3.91Hz (s, 3H), 3.86 (t, J=6.58Hz, 4H),
3.80 (t, J=6.58Hz, 4H), 3.54 (br s, 2H), 3.38 (m, 2H), 3.16 (t, J=7.56Hz,
2H), 3.10 (br s, 2H), 2.55 (m, 2H), 2.04 (m, 2H), 1.92 (br s, 4H), and 1.18 (d,
J=6.25Hz, 3H). 13C NMR (151MHz, DMSO‐d6): δ (ppm) =171.7, 158.8
(TFA), 158.5 (TFA), 158.3 (TFA), 158.1 (TFA), 151.7, 145.4, 134.3, 122.0,
117.4 (TFA), 115.5 (TFA), 114.6, 112.7, 94.0, 66.5, 57.4, 54.9 and 53.3
(the two carbons adjacent to the pyrrolidine nitrogen yielded two sig-
nals), 52.4 (2C), 41.2 (2C), 32.4, 30.8, 24.1, 22.6 (2C), 21.1, and 17.7. RP‐
HPLC (220nm): 96% (tR = 10.2min, k=2.4). HRMS (ESI): m/z
[M+H]+ calcd. for C23H35Cl2N4O2




pyrrolidinooethyl amide) bis(hydrotrifluoroacetate) (11)
Compound 11 was prepared according to the general procedure
for the amide bond formation (in the microwave). The reaction was
carried out using isobendamustine (100mg, 0.279mmol, 1.0 eq),
TBTU (89.6 mg, 0.279mmol, 1.0 eq), DIPEA (97.2 µl, 0.558mmol, 2.0
eq), 2‐(pyrrolidin‐1‐yl)ethan‐1‐amine (38.9 µl, 0.279mmol, 1.0 eq),
and DMF (1ml). Preparative HPLC (0–30min: MeCN/0.1% aq TFA
15:85–55:45, tR = 14.2min) yielded 11 as a yellow resin (77.2 mg,
0.113mmol, 41%). 1H NMR (600MHz, DMSO‐d6): δ (ppm) = 14.98
(br s, 1H), 10.02 (s, 1H), 8.24 (t, J = 5.69 Hz, 1H), 7.58 (d, J = 9.07 Hz,
1H), 7.11 (d, J = 2.25 Hz, 1H), 7.08 (dd, J = 9.07 Hz, J = 2.25, 1H), 3.91
(s, 3H), 3.86 (t, J = 6.51 Hz, 4H), 3.80 (t, J = 6.51 Hz, 4H), 3.57 (br s,
2H), 3.36 (m, 2H), 3.17 (s, 2H), 3.13 (t, J = 7.71 Hz, 2H), 2.99 (br s,
2H), 2.27 (t, J = 7.24 Hz, 2H), 2.01 (m, 2H), and 1.92 (m, 4H). 13C NMR
(151MHz, DMSO‐d6): δ (ppm) = 171.9, 158.8 (TFA), 158.6 (TFA),
158.4 (TFA), 158.1 (TFA), 151.9, 145.4, 134.3, 122.0, 117.6 (TFA),
115.6 (TFA), 114.6, 112.7, 94.0, 53.3 (2C), 53.1, 52.4 (2C), 41.2 (2C),
35.0, 33.7, 30.8, 24.3, 22.5 (2C), and 21.8. RP‐HPLC (220 nm): 96%
(tR = 9.0 min, k = 2.0). HRMS (ESI): m/z [M+H]
+ calcd. for
C22H34Cl2N5O
+: 454.2135, found: 454.2135. C22H33Cl2N5O·C4H2-
F6O4 (454.44 + 228.05).
1‐(Pyrrolidin‐1‐yl)propan‐2‐yl 4‐{4‐[bis(2‐chloroethyl)amino]phenyl}‐
butanoate (chlorambucil 1‐methyl‐2‐pyrrolidinoethyl ester)
hydrotrifluoroacetate (12)
Compound 12 was prepared according to the general procedure
2 for the ester bond formation. The reaction was carried out using
chlorambucil (80mg, 0.263mmol, 1.0 eq), TBTU (84.4 mg,
0.263mmol, 1.0 eq), DIPEA (89.4 µl, 0.526mmol, 2.0 eq), 1‐
(pyrrolidin‐1‐yl)propan‐2‐ol (51.0 µl, 0.394mmol, 1.5 eq), and DMF
(1ml). Preparative HPLC (0–30min: MeCN/0.1% aq TFA
33:67–69:31, tR = 15.5min) yielded 12 as a brownish resin (49.2 mg,
0.093mmol, 35%). More than one diastereoisomer was evident in
the NMR spectra. 1H NMR (600MHz, DMSO‐d6) δ (ppm) 9.99 (br s,
1H), 7.02 (d, J = 8.6 Hz, 2H), 6.67 (d, J = 8.8 Hz, 2H), 5.13 (m, 1H), 3.69
(m, 8H), 3.59–3.45 (m, 2H), 3.44–3.30 (m, 2H), 3.12–3.99 (m, 2H),
2.49–2.45 (m, 2H), 2.38–2.27 (m, 2H), 1.99 (m, 2H), 1.86 (m, 2H), 1.77
(m, 2H), and 1.20 (d, J = 6.3 Hz, 3H). 13C NMR (151MHz, DMSO‐d6) δ
(ppm) 172.3, 158.6 (TFA), 158.3 (TFA), 158.1 (TFA), 157.9 (TFA),
144.5, 129.4, 129.3 (2C), 117.5 (TFA), 115.6 (TFA), 111.9 (2C), 66.1,
57.4, 54.9 and 53.3 (the two carbons adjacent to the pyrrolidine
nitrogen yielded two signals), 52.2 (2C), 41.2 (2C), 33.2, 33.0, 26.3,
22.7 and 22.5 (the two pyrrolidine carbons not adjacent to the ni-
trogen yielded two signals), and 17.7. RP‐HPLC (220 nm): 92% (tR =
9.2min, k = 6.2) (the second peak in the chromatogram is not due to
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impurity but due to decomposition in the aqueous HPLC eluent).
HRMS (ESI): m/z [M+H]+ calcd. for C21H33Cl2N2O2
+: 415.1914,
found: 415.1924. C21H32Cl2N2O2·C2HF3O2 (414.18 + 114.02).
4‐{4‐[Bis(2‐chloroethyl)amino]phenyl}‐N‐[2‐(pyrrolidin‐1‐yl)ethyl]‐
butanamide (chlorambucil 2‐pyrrolidinooethyl amide)
hydrotrifluoroacetate (13)[32]
Compound 13 was prepared according to the general procedure for
the amide bond formation (in the microwave). The reaction was carried
out using chlorambucil (100mg, 0.329mmol, 1.0 eq), TBTU (105.5mg,
0.329mmol, 1.0 eq), DIPEA (111.8 µl, 0.657mmol, 2.0 eq), 2‐(pyrrolidin‐
1‐yl)ethan‐1‐amine (45.8 µl, 0.362mmol, 1.1 eq), and DMF (1ml). Two-
fold purification by preparative HPLC (0–30min: MeCN/0.1% aq TFA
28:72–68:32, tR =13.5min) yielded 13 as a yellowish resin (75.5mg,
0.147mmol, 45%). 1H NMR (600MHz, DMSO‐d6) δ (ppm) 9.80 (br s, 1H),
8.07 (m, 1H), 7.01 (d, J=8.6Hz, 2H), 6.66 (d, J=8.6Hz, 2H), 3.69 (m, 8H),
3.57 (m, 2H), 3.36 (q, J=6.1Hz, 2H), 3.18 (q, J=6.0Hz, 2H), 3.00 (m, 2H),
2.44 (t, J=7.7Hz, 2H), 2.10 (t, J=7.4Hz, 2H), 1.99 (m, 2H), 1.85 (m, 2H),
and 1.74 (m, 2H). 13C NMR (151MHz, DMSO‐d6) δ (ppm) 172.8, 158.6
(TFA), 158.4 (TFA), 158.2 (TFA), 158.0 (TFA), 144.4, 129.8, 129.3 (2C),
117. 6 (TFA), 115.6 (TFA), 111.9 (2C), 53.4 (2C), 53.3, 52.2 (2C), 41.2
(2C), 35.0, 34.8, 33.6, 27.0, and 22.5 (2C). RP‐HPLC (220 nm): 92%
(tR = 14.3min, k=3.7) (the second peak in the chromatogram is not due
to impurity but due to decomposition in the aqueous HPLC eluent).
HRMS (ESI): m/z [M+H]+ calcd. for C20H32Cl2N3O
+: 400.1917, found:
400.1925. C20H31Cl2N3O·C2HF3O2 (399.18+ 114.02).
(S)‐3‐{4‐[Bis(2‐chloroethyl)amino]phenyl}‐2‐[(tert‐butoxycarbonyl)‐
amino]propanoic acid (boc‐melphalan) (14) [34,35]
Melphalan (38.0mg, 0.125mmol, 1.0 eq) and NaHCO3 (31.4 mg,
0.374mmol, 3.0 eq) were dissolved in tetrahydrofuran/H2O 1:1
(1 ml and Boc2O [di‐tert‐butyl dicarbonate]; 42.9 µl, 0.1787 mmol, 1.5
eq) was added and the mixture stirred at room temperature for
30min. The suspension was diluted with EtOAc and the organic layer
was washed with 1 M HCl aq and brine, dried over Na2SO4, and
concentrated under reduced pressure to a brown oil, which was used
in subsequent reactions without further purification. 1H NMR
(400MHz, CDCl3) δ (ppm) 9.79 (s, 1H), 7.07 (d, J = 7.8 Hz, 2H), 6.62
(d, J = 8.6 Hz, 2H), 4.96 (d, J = 7.4 Hz, 1H), 4.55 (m, 1H), 3.70 (m, 4H),
3.61 (m, 4H), 3.13–2.96 (m, 2H), and 1.52 (s, 9H). HRMS (ESI): m/z
[M+H]+ calcd. for C22H34Cl2N5O





Compound 15 was prepared according to the general procedure
2 for the ester bond formation. The reaction was carried out using
boc‐melphalan (133mg, 0.328mmol, 1.0 eq), TBTU (105mg,
0.328mmol, 1.0 eq), DIPEA (111 µl, 0.655mmol, 2.0 eq), 1‐
(pyrrolidin‐1‐yl)propan‐2‐ol (63.5 µl, 0.491mmol, 1.5 eq), and DMF
(3ml). The mixture was diluted with brine (50ml) and the product
was extracted with EtOAc (3 × 50ml). The combined organic layers
were dried over Na2SO4 and concentrated under reduced pressure.
For N‐boc deprotection, the residue was dissolved in DCM (2ml), and
TFA (0.5 ml) was added and the solution was stirred at room tem-
perature for 2 h. Evaporation of the volatiles and purification by
preparative HPLC (0–30min: MeCN/0.1% aq TFA 21:79–57:43,
tR = 13.5min) yielded 15 as a brown resin (20.2mg, 0.031mmol, 10%
for protection, coupling, and deprotection). More than one diaster-
eoisomer was evident in the NMR spectra. 1H NMR (600MHz,
DMSO‐d6) δ (ppm) 10.07 (br s, 1H), 8.57 (m, 3H), 7.08 (m, 2H), 6.72
(m, 2H), 5.16 (m, 1H), 4.33–4.15 (m, 1H), 3.72 (m, 8H), 3.62–3.31 (m,
4H), 3.12–2.91 (m, 4H), 2.05–1.74 (m, 4H), 1.27–1.12 (m, 3H). 13C
NMR (151MHz, DMSO‐d6) δ (ppm) 168.7, 168.0, 158.8 (TFA), 158.6
(TFA), 158.4 (TFA), 158.2 (TFA), 145.7, 145.7, 130.7, 130.6 (2C),
122.3, 122.0, 117.6 (TFA), 115.6 (TFA), 112.0 (2C), 68.9, 68.6, 57.1,
57.0, 54.8, 53.7, 53.5, 53.3, 53.0, 52.0 (2C), 41.1 (2C), 34.8, 34.8, 22.6
(2C), 17.3, and 17.2. RP‐HPLC (220 nm): 98% (tR = 5.5 min, k = 3.4).
HRMS (ESI): m/z [M+H]+ calcd. for C20H32Cl2N3O2
+: 416.1866,
found: 416.1871. C20H31Cl2N3O2·C4H2F6O4 (416.39 + 228.05).
(S)‐2‐Amino‐3‐{4‐[bis(2‐chloroethyl)amino]phenyl}‐N‐[3‐(pyrrolidin‐
1‐yl)propyl]propanamide (melphalan 3‐pyrrolidinopropyl amide)
bis(hydrotrifluoroacetate) (16)
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Compound 16 was prepared according to the general procedure
for the amide bond formation (in the microwave). The reaction was
carried out using boc‐melphalan (64.2 mg, 0.125mmol, 1.0 eq), TBTU
(40.0 mg, 0.125mmol, 1.0 eq), DIPEA (65.1 µl, 0.374mmol, 3.0 eq), 3‐
(pyrrolidin‐1‐yl)propan‐1‐amine (47.3 µl, 0.374mmol, 3.0 eq), and
DMF (1ml). The mixture was diluted with brine (20ml) and the
product was extracted with EtOAc (3 × 20ml). The combined organic
layers were dried over Na2SO4 and concentrated under reduced
pressure. For N‐boc deprotection, the residue was dissolved in DCM
(0.5ml), and TFA (0.5ml) was added and the solution was stirred at
room temperature for 2 h. Evaporation of the volatiles and purification
by preparative HPLC (0–30min: MeCN/0.1% aq TFA 15:85–55:45,
tR = 14.4min) yielded 16 as a brownish resin (22.9mg, 0.036mmol, 29%
for protection, coupling and deprotection). More than one diastereoi-
somer was evident in the NMR spectra. 1H NMR (600MHz, DMSO‐d6)
δ (ppm) 10.08 (s, 1H), 8.59 (t, J = 5.8Hz, 1H), 8.20 (br s, 3H), 7.06 (d,
J = 8.7Hz, 2H), 6.71 (d, J= 8.8Hz, 2H), 3.86 (m, 1H), 3.71 (s, 8H), 3.51
(m, 2H), 3.21–3.09 (m, 2H), 3.07–2.98 (m, 2H), 2.95–2.83 (m, 4H),
2.03–1.82 (m, 4H), and 1.79–1.67 (m, 2H). 13C NMR (151MHz, DMSO‐
d6) δ (ppm) 168.3, 158.8 (TFA), 158.6 (TFA), 158.4 (TFA), 158.2 (TFA),
145.5, 130.5 (2C), 122.8, 117.8 (TFA), 115.9 (TFA), 112.0 (2C), 53.9,
53.3 and 53.2 (the two carbons adjacent to the pyrrolidine nitrogen
yielded two signals), 52.1 (2C), 51.8, 41.2 (2C), 36.1, 35.9, 25.4, and 22.6
(2C). RP‐HPLC (220 nm): 97% (tR = 8.9min, k= 1.9). HRMS (ESI): m/z
[M+H]+ calcd. for C20H33Cl2N4O
+: 415.2026, found: 415.2034.
C20H32Cl2N4O·C4H2F6O4 (415.40 + 228.05).
4.2 | Biology
4.2.1 | General experimental conditions
Materials: Commodity chemicals and solvents were purchased from
commercial suppliers (Sigma Aldrich, Merck, VWR, Thermo Fisher
Scientific, Invitrogen, and Serva). Millipore water was used
throughout for the preparation of buffers and aqueous reagent so-
lutions. The pH of buffers was adjusted with NaOH aq or HCl aq. All
cell lines were purchased from the ATCC (American Type Culture
Collection). Tissue culture flasks were procured from Sarstedt. The
RPMI‐1640 medium was purchased from Sigma Aldrich. Fetal calf
serum (FCS) and trypsin/EDTA solution was purchased from
Biochrom. Ninety‐six‐well microplates (PS, clear, F‐bottom, with
lid, sterile) were purchased from Greiner Bio‐One.
Stock solutions: The test compounds were dissolved in DMSO at
1000 times the final concentrations in the chemosensitivity assay.
Instruments: Absorbance measurements were carried out with a
GENios Pro microplate reader (equipped with a Xenon arc lamp; Tecan).
Software: All biological data were analyzed with GraphPad Prism
5 (GraphPad Software).
4.2.2 | Cell culture
All cell lines were cultured in the RPMI‐1640 medium containing
110 mg/l sodium pyruvate, 2.4 g/l HEPES, and 2.0 g/l NaHCO3, and
supplemented with 10% (v/v) FCS at 37°C in a water‐saturated at-
mosphere containing 5% CO2. Cells were passaged after treatment
with a solution containing 0.05% trypsin and 0.025% EDTA. All cells
were routinely monitored for mycoplasma contamination by poly-
merase chain reaction using the Venor®GeM mycoplasma detection
kit (Minerva Biolabs), which were found to be negative.
4.2.3 | Chemosensitivity assay[33]
Cells were seeded into 96‐well plates at a density of 1500 cells per well
(MG‐63 and HT‐29 cells) or a density of 3000 cells per well (SK‐MEL‐3
cells) (100 μl/well), and they were allowed to attach to the surface of the
microplates in a water‐saturated atmosphere containing 5% CO2 at 37°C
overnight. The next day, fresh medium containing the test compounds at
two‐fold final concentrations was added (100 µl/well; giving a final vo-
lume of 200 µl/well). On each plate, vinblastine at a final concentration of
300nM served as reference cytostatic (positive control); the vehicle
DMSO (0.1%) served as a negative control to monitor cell growth in the
absence of a drug. Each concentration was measured in octuplicate and
the negative control in a 16‐fold replication. Growth of the cells was
stopped after different periods of time by removal of medium and fixa-
tion with 2% (v/v) glutardialdehyde in phosphate‐buffered saline (100µl/
well). All the plates were stored at 4°C until the end of the experiment
and afterward stained with 0.02% crystal violet in water (100 µl/well) for
20min. Excess dye was removed by rinsing the plates with water three
times. Crystal violet bound by the fixed cells was redissolved in 70%
ethanol (180µl/well) while shaking the microplates for 2–3 h. The ab-
sorbance (580 nm) as a parameter proportional to the cell mass was
measured using a GENios Pro microplate reader.







/ [%] = × 100,corr
0
0
where T is the mean absorbance of the treated cells, C is the mean
absorbance of the negative controls, and C0 is the mean absorbance of
the cells at the time of compound addition (t0). When the absorbance of
treated cells T was lower than at the beginning of the experiment (C0),
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